Early Results from Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Demonstrate Clinical Activity and Corresponding Changes in Cytokine Levels Consistent with ITK Inhibition Mechanism of...
Data demonstrated in vitro and in vivo ITK inhibition with soquelitinib induced switching of proinflammatory Th17 cells into anti-inflammatory Treg cells Publication confirms and extends...
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024 Soquelitinib Registration Phase 3 Trial in Peripheral T Cell...
Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company™s selective ITK inhibitor Corvus anticipates releasing initial clinical data from...